The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets
|
|---|---|
| Published in |
Frontiers in Pharmacology, May 2018
|
| DOI | 10.3389/fphar.2018.00431 |
| Pubmed ID | |
| Authors |
Paul A. Insel, Krishna Sriram, Shu Z. Wiley, Andrea Wilderman, Trishna Katakia, Thalia McCann, Hiroshi Yokouchi, Lingzhi Zhang, Ross Corriden, Dongling Liu, Michael E. Feigin, Randall P. French, Andrew M. Lowy, Fiona Murray |
| Abstract |
G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are rarely targeted for cancer treatment, except for certain endocrine and hormone-responsive tumors. Limited knowledge regarding GPCR expression in cancer cells likely has contributed to this lack of use of GPCR-targeted drugs as cancer therapeutics. We thus undertook GPCRomic studies to define the expression of endoGPCRs (which respond to endogenous molecules such as hormones, neurotransmitters and metabolites) in multiple types of cancer cells. Using TaqMan qPCR arrays to quantify the mRNA expression of ∼340 such GPCRs, we found that human chronic lymphocytic leukemia (CLL) cells/stromal cells associated with CLL, breast cancer cell lines, colon cancer cell lines, pancreatic ductal adenocarcinoma (PDAC) cells, cancer associated fibroblasts (CAFs), and PDAC tumors express 50 to >100 GPCRs, including many orphan GPCRs (which lack known physiologic agonists). Limited prior data exist regarding the expression or function of most of the highly expressed GPCRs in these cancer cells and tumors. Independent results from public cancer gene expression databases confirm the expression of such GPCRs. We propose that highly expressed GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and GPR68 in PDAC CAFs) may contribute to the malignant phenotype, serve as biomarkers and/or may be novel therapeutic targets for the treatment of cancer. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 40% |
| United Kingdom | 2 | 13% |
| Canada | 1 | 7% |
| Unknown | 6 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 6 | 40% |
| Members of the public | 6 | 40% |
| Science communicators (journalists, bloggers, editors) | 2 | 13% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 198 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 198 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 28 | 14% |
| Student > Bachelor | 27 | 14% |
| Researcher | 26 | 13% |
| Student > Master | 23 | 12% |
| Other | 10 | 5% |
| Other | 30 | 15% |
| Unknown | 54 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 61 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 25 | 13% |
| Agricultural and Biological Sciences | 17 | 9% |
| Medicine and Dentistry | 14 | 7% |
| Chemistry | 8 | 4% |
| Other | 17 | 9% |
| Unknown | 56 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2022.
All research outputs
#1,799,438
of 22,986,950 outputs
Outputs from Frontiers in Pharmacology
#646
of 16,272 outputs
Outputs of similar age
#40,941
of 329,903 outputs
Outputs of similar age from Frontiers in Pharmacology
#22
of 401 outputs
Altmetric has tracked 22,986,950 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,272 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,903 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 401 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.